Nature Biotechnology 2005 Cormac Sheridan - Abstracts
| Nature Biotechnology 2005 Cormac Sheridan | |||||
| Title | Subject | Authors | |||
|---|---|---|---|---|---|
| Antiinfective biotechs face partnering gap. | Business | Cormac Sheridan | |||
| Chiron's manufacturing misfortunes boost competitors. | Business | Cormac Sheridan | |||
| Cord blood cell therapy trial suspended. | Business | Cormac Sheridan | |||
| Cost-effectiveness data on biologics needed. | Business | Cormac Sheridan | |||
| EPO neem patent revocation revives biopiracy debate. | Business | Cormac Sheridan | |||
| It came from beneath the sea. | Business | Cormac Sheridan | |||
| New biotech oasis?(in middle east countries) | Business | Cormac Sheridan | |||
| Politics torpedo biotech as EU priority. | Business | Cormac Sheridan | |||
| Protein chip companies turn to biomarkers. | Business | Cormac Sheridan | |||
| Spanish wishful thinking towards biotech. | Business | Cormac Sheridan | |||
| The business of making vaccines. | Business | Cormac Sheridan | |||
| Tysabri raises alarm bells on drug class. | Business | Cormac Sheridan | |||
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.